BACKGROUND: Plantar warts are typically resistant to treatment. In recent years, treatments have included administration of intralesional tuberculin; measles, mumps, @entity2462 vaccine; and Candida albicans antigen immunotherapy. To the best of our knowledge, there are no reports of intralesional @entity560 administration for the treatment of warts. AIM: To evaluate the efficacy and safety of intralesional @entity560 treatment for @entity4891 . METHODS: Twenty @entity1 with single or @entity4891 were included in this study. @entity3875 (0.2 mL, 7.5 mg/mL) was injected into the base of the warts after @entity5403 (0.1 mL, 20 mg/mL) injection. A maximum of 5 warts were treated in 1 session, with at maximum 2 injections performed at 4-week intervals. RESULTS: In total, 16 of 20 @entity1 (80%) showed complete resolution of warts, and 1 @entity1 showed partial resolution. Three @entity1 failed to show any response. No recurrence or serious adverse effects were observed. CONCLUSION: Intralesional @entity3875 may be an effective treatment option for warts.

Intralesional XXXX Injection May Be an Effective Treatment Option for Warts.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5403 :: ('MESH:D011318', 'Chemical') :: ['prilocaine'] @entity3875 :: ('MESH:D002762', 'Chemical') :: ['Vitamin D3', 'vitamin D3'] @entity2462 :: ('MESH:D012409', 'Disease') :: ['rubella'] @entity4891 :: ('MESH:D014860', 'Disease') :: ['plantar warts', 'multiple plantar warts'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D']
@entity560 :: (MESH:D014807,Chemical) :: ['Vitamin D']
